Intrarenal dopaminergic system regulates renin expression

Hypertension

Volumn 53, Issue 3, 2009, Pages 564-570

  Zhang, Ming Zhi ^a   Yao, Bing ^a   Fang, Xiaofeng ^a   Wang, Suwan ^a   Smith, James P ^a   Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COX 2; Dopamine; Kidney; Macula densa; Proximal tubule; Renin; Salt reabsorption

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYCLOOXYGENASE 2; DOPAMINE; FENOLDOPAM; RENIN; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PTGS2 PROTEIN, MOUSE; PTGS2 PROTEIN, RAT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; DRUG POTENTIATION; FEMALE; GENETICS; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; CYCLOOXYGENASE 2; DOPAMINE; DOPAMINE AGONISTS; FEMALE; FENOLDOPAM; KIDNEY TUBULES, DISTAL; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, KNOCKOUT; RATS; RECEPTORS, DOPAMINE D1; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE;

EID: 61749084993     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.127035     Document Type: Article

References (34)

1. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 1996;97:2745-2752.
2. Aperia AC. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol. 2000;62:621-647.
3. Jose PA, Eisner GM, Felder RA. Dopamine and the kidney: a role in hypertension? Curr Opin Nephrol Hypertens. 2003;12:189-194.
4. Pedrosa R, Jose PA, Soares-da-Silva P. Defective Dl-like receptor-mediated inhibition of the Cl-/HCO3-exchanger in immortalized SHR proximal tubular epithelial cells. Am J Physiol Renal Physiol. 2004;286: F1120-F1126.
5. Carey RM. Theodore Cooper Lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension. 2001; 38:297-302.
6. Harris RC, Zhang MZ, Cheng HF. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand. 2004;181:543-547.
7. Kim SM, Chen L, Faulhaber-Walter R, Oppermann M, Huang Y, Mizel D, Briggs JP, Schnermann J. Regulation of renin secretion and expression in mice deficient in {beta}1- and {beta}2-adrenergic receptors. Hypertension. 2007;50:103-109.
8. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol. 1998;274:R263-R279.
9. Schnermann J, Traynor T, Yang T, Arend L, Huang YG, Smart A, Briggs JP. Tubuloglomerular feedback: new concepts and developments. Kidney Int. 1998;67(suppl):S40-S45.
10. Kurtz A, Delia Bruna R, Pratz J, Cavero I. Rat Juxtaglomerular cells are endowed with DA-1 dopamine receptors mediating renin release. J Cardiovasc Pharmacol. 1988;12:658-663.
11. Antonipillai I, Broers MI, Lang D. Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release. Hypertension. 1989;13:463-468.
12. Yamaguchi I, Yao L, Sanada H, Ozono R, Mouradian MM, Jose PA, Carey RM, Felder RA. Dopamine D1A receptors and renin release in rat Juxtaglomerular cells. Hypertension. 1997;29:962-968.
13. Jeffrey RF, MacDonald TM, Marwick K, Lee MR. The effect of carbidopa and indomethacin on the renal response to gamma-L-glutamyl-L-dopa in normal man. Br J Clin Pharmacol. 1988;25:195-201.
14. Worth DP, Harvey JN, Brown J, Worral A, Lee MR. Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous gamma-L-glutamyl-L-dopa. Br J Clin Pharmacol. 1986;21: 497-502.
15. Kaulhausen H, Oney T, Leyendecker G. Inhibition of the renin-aldosterone axis and of prolactin secretion during pregnancy by L-dopa. Br J Obstet Gynaecol. 1982;89:483-488.
16. Vikse A, Bugge J, Dahl E, Kiil F. Dissociation between renal prostaglandin E2 and renin release. Effects of glucagon, dopamine and cyclic AMP in dogs. Acta Physiol Scand. 1985;125:619-626.
17. Harvey JN, Worth DP, Brown J, Lee MR. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol. 1985;19:21-27.
18. Mizoguchi H, Dzau VJ, Siwek LG, Barger AC. Effect of intrarenal administration of dopamine on renin release in conscious dogs. Am J Physiol. 1983;244:H39-H45.
19. Montier F, Katchadourian P, Pratz J, Cavero I. Increase in plasma renin activity evoked by fenoldopam in dogs is directly mediated by dopamine I receptor stimulation. J Cardiovasc Pharmacol. 1989;13:739-747.
20. Kim SM, Chen L, Mizel D, Huang YG, Briggs JP, Schnermann J. Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol. 2007;292: F415-F422.
21. Harvey JN, Worth DP, Brown J, Lee MR. Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br J Clin Pharmacol. 1986;21:53-61.
22. Peti-Peterdi J, Komlosi P, Fuson AL, Guan Y, Schneider A, Qi Z, Redha R, Rosivall L, Breyer MD, Bell PD. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest. 2003; 112:76-82.
23. Zhang MZ, Yao B, McKanna JA, Harris RC. Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems. Am J Physiol Renal Physiol. 2005;288:F840-F845.
24. Zhang MZ, Wang JL, Cheng HF, Harris RC, McKanna JA. Cyclooxygenase-2 in rat nephron development. Am J Physiol. 1997;273: F994-F1002.
25. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409.
26. Cheng HF, Wang JL, Zhang MZ, Wang SW, McKanna JA, Harris RC. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol. 2001;280: F449-F456.
27. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A. 1998;95:9991-9996.
28. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548-1557.
29. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A. 2005;102:2174-2179.
30. Zhang MZ, Yao B, Cheng HF, Wang SW, Inagami T, Harris RC. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci U S A. 2006; 103:16045-16050.
31. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-2510.
32. Helkamaa T, Mannisto PT, Rauhala P, Cheng ZJ, Finckenberg P, Huotari M, Gogos JA, Karayiorgou M, Mervaala EM. Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. J Hypertens. 2003;21:2365-2374.
33. Wagner C, Vitzthum H, Castrop H, Schumacher K, Bucher M, Albertin S, Coffman TM, Arendshorst WJ, Kurtz A. Differential regulation of renin and Cox-2 expression in the renal cortex of C57B1/6 mice. Pflugers Arch. 2003;447:214-222.
34. de Toledo FG, Thompson MA, Bolliger C, Tyce GM, Dousa TP. Gamma-L-glutamyl-L-DOPA inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate. Kidney Int. 1999;55:1832-1842.